JonesTrading analyst Debanjana Chatterjee has maintained their bullish stance on EYPT stock, giving a Buy rating on November 20.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Debanjana Chatterjee’s rating is based on the promising outlook for EyePoint Pharmaceuticals’ wet AMD therapy, Duravyu, which is expected to play a significant role in the evolving treatment landscape by 2026. The company’s strategic regulatory path for wet AMD approval is well-established, which could potentially mitigate risks compared to competitors adopting more innovative trial designs.
Furthermore, the upcoming pivotal data readouts for Duravyu, along with other emerging therapies, are anticipated to be paradigm-shifting, providing EyePoint Pharmaceuticals with a competitive edge. The company’s strong cash position of $366 million further supports its capacity to advance its pipeline and capitalize on these opportunities. These factors collectively contribute to the Buy rating, reflecting confidence in EyePoint Pharmaceuticals’ potential for growth and market impact.
In another report released on November 20, H.C. Wainwright also reiterated a Buy rating on the stock with a $23.00 price target.